Viracta Therapeutics, Inc. (VIRX)
NASDAQ: VIRX · Real-Time Price · USD
0.177
+0.016 (10.19%)
At close: Jan 2, 2025, 3:59 PM
0.173
-0.004 (-2.43%)
After-hours: Jan 2, 2025, 4:05 PM EST
Viracta Therapeutics Stock Forecast
VIRX's stock price has decreased by -69.28% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for VIRX stock have an average target of 5.00, with a low estimate of 2.00 and a high estimate of 11. The average target predicts an increase of 2,720.08% from the current stock price of 0.18.
Analyst Consensus: Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for VIRX stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $4 → $2 | Buy | Maintains | $4 → $2 | +1,028.03% | Nov 14, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $5 → $3 | Buy → Hold | Downgrades | $5 → $3 | +1,592.05% | Aug 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +2,156.06% | Aug 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $13 → $11 | Buy | Maintains | $13 → $11 | +6,104.17% | May 23, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $13 | Buy | Maintains | $13 | +7,232.21% | Apr 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.82
from -1.32
EPS Next Year
-0.37
from -0.82
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | |||
| Avg | n/a | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.84 | -0.38 | -0.42 | |||
| Avg | -0.82 | -0.37 | -0.41 | |||
| Low | -0.78 | -0.35 | -0.39 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.